REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The Companyâs NAV Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. The Companyâs mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing in vivo gene therapy products based on the Companyâs NAV Technology Platform. The Company seeks to accomplish this mission through a combination of internal development efforts and the efforts of the Companyâs third-party licensees. Source
No articles found.
Intellia Therapeutics is a leading genome editing company focused on developing cu...
Intellia Therapeutics is a leading genome editi...
Premier operates one of the nationâs largest performance improvement alliances o...
Premier operates one of the nationâs largest ...
Vivoo is a wellness assistant that consists of urinalysis test strips and a mobile...
Vivoo is a wellness assistant that consists of ...
ANGLE is a world leading liquid biopsy company with pioneering products in cancer ...
ANGLE is a world leading liquid biopsy company ...
Cool your patients to a target temperature of 33ÂşC in about 30 minutes with Life ...
Cool your patients to a target temperature of 3...
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device compan...
Cardiovascular Systems, Inc., based in St. Paul...
We are a gene therapy company dedicated to developing and commercializing novel tr...
We are a gene therapy company dedicated to deve...
Join the National Investor Network and get the latest information with your interests in mind.